<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00044135</url>
  </required_header>
  <id_info>
    <org_study_id>L-FMAU-102 B</org_study_id>
    <nct_id>NCT00044135</nct_id>
  </id_info>
  <brief_title>A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.</brief_title>
  <official_title>A Phase II, Randomized, Partially-Blinded Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of 12 Weeks of Treatment with Clevudine (10 mg, 30 mg or 50 mg QD) in Patients Infected with Hepatitis B Virus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Triangle Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Triangle Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and effectiveness of 12 weeks of treatment
      with clevudine, at one of three doses, in patients chronically infected with hepatitis B
      virus.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2002</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Hepatitis B</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clevudine (drug)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HBV DNA positive with DNA levels at screening greater than or equal to 3,000,000
             copies/mL.

          -  Documented to be HBsAg positive for &gt; 6 months OR HBsAg positive and IgM anti-HBc
             negative and anti-HBs negative. Patients may be HBeAg positive, and anti-HBe negative
             OR HBeAg negative (pre-core mutant) and anti-HBe positive.

          -  HBeAg positive and anti-HBe negative OR HBeAg negative (pre-core mutant) and anti-HBe
             positive with positive HBsAg for the previous 6 months

          -  AST and ALT levels which are less than or equal to 10 times the upper limit of normal.

          -  Bilirubin levels less than or equal to 1.5 x ULN or bilirubin levels &gt; 1.5 x ULN with
             diagnosis of Gilbertâ€™s disease and conjugated bilirubin within normal limits.

        Exclusion Criteria:

          -  Currently receiving antiviral, immunomodulatory or corticosteroid therapy

          -  Previous treatment with lamivudine, lobucavir, adefovir, famciclovir, or any other
             investigational nucleoside for HBV infection

          -  Previous treatment with interferon must have ended at least 6 months prior to
             screening visit

          -  History of ascites, variceal hemorrhage or hepatic encephalopathy

          -  Co-infection with HCV or HIV

          -  Evidence of cirrhosis or hepatocellular carcinoma (alpha fetoprotein)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital, Jefferson Medical College</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Viridae</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z1Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia, Downtown Infectious Disease Clinic</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital, Department of Medicine and Therapeutics</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Hong Kong, Clinical Trials Centre, Faculty of Medicine, Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Beaujon, Service Hepatologie Centre Pierre Abrami</name>
      <address>
        <city>Clichy</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dieu, Service Hepatogastroenterologie-endoscopie</name>
      <address>
        <city>Lyon</city>
        <zip>69288</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital St Louis, Service de Medecine Interne</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Brabois Chu de Nancy, Service d'Hepato-gastroenterologie</name>
      <address>
        <city>Vandoeuvre</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital, Division of Gastroenterology, Department of Medicine</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>France</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2002</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2002</study_first_submitted>
  <study_first_submitted_qc>August 20, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2002</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>clevudine</keyword>
  <keyword>hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clevudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

